Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 2/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115859 | 1.00 | TSHR (0.65) | TSHRKDM4ECPB1LDHASRR | |
| SCHEMBL7771088 | 0.92 | TSHR (0.52) | TSHRKDM4ECPB1LDHASRR | |
| SCHEMBL7771087 | 0.92 | TSHR (0.52) | TSHRKDM4ECPB1LDHASRR | |
| SCHEMBL8209991 | 0.85 | KDM4E (0.46) | TSHRKDM4ECPB1LDHAABAT | |
| SCHEMBL30173709 | 0.85 | KDM4E (0.46) | TSHRKDM4ECPB1LDHAABAT | |
| SCHEMBL24180793 | 0.81 | KDM4E (0.43) | TSHRKDM4ECPB1ALOX15ABAT | |
| Aconitic Acid SCHEMBL22334 | 0.79 | TSHR (1.00) | TSHRKDM4ECPB1LDHASRR | |
| SCHEMBL7771390 | 0.79 | TSHR (0.39) | TSHRKDM4ECPB1LDHACYP2C19 | |
| SCHEMBL7771392 | 0.79 | TSHR (0.39) | TSHRKDM4ECPB1LDHACYP2C19 | |
| Aconitic Acid SCHEMBL219037 | 0.79 | TSHR (1.00) | TSHRKDM4ECPB1LDHASRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3641832-B1 | NUCLEIC ACID NANOCAPSULES FOR DRUG DELIVERY AND TARGETED GENE KNOCKDOWN | UNIV CONNECTICUT (US) | 2024-09-11 | — | — | EP | claimed |
| EP-0080451-B1 | METHOD AND COMPOSITION FOR DIENE RUBBER TREATMENT | MONSANTO COMPANY (US) | 1985-09-18 | — | — | EP | claimed |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | PIERRE FABRE MEDICAMENT (FR) | 2026-05-28 | — | — | US | disclosed |
| EP-4748862-A2 | HETERODIMERIC PROTEINS | Xencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3620473-B1 | NOVEL HETERODIMERIC PROTEINS | XENCOR INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748856-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS | Lentigen Technology, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260139073-A1 | Antigen Binding Proteins | GLAXO GROUP LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4739396-A1 | HUMANIZED 40H3 ANTIBODY | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12624104-B2 | Compositions and methods for treating cancer with anti-CD19 immunotherapy | LENTIGEN TECHNOLOGY, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4737482-A1 | HUMANIZED ANTI-MYCT1 ANTIBODY AND USE THEREOF | Atheon Bio, Inc. (KR) | 2026-05-06 | — | — | EP | disclosed |
| EP-3817770-B1 | ANTI-STEAP1 ANTIGEN-BINDING PROTEIN | AMGEN INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-11248054-B2 | Anti-IL1RAP antibodies and antibody drug conjugates | BLUEFIN BIOMEDICINE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2022031652-A1 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-2099823-B2 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
| US-20220031859-A1 | HERBOXIDIENE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| EP-2609932-B1 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2022-02-02 | — | — | EP | disclosed |
| US-11230610-B2 | Bivalent antibodies masked by coiled coils | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20110060123-A1 | CHARGE CONVERSIONAL TERNARY POLYPLEX | THE UNIVERSITY OF TOKYO (JP) | 2011-03-10 | — | — | US | disclosed |
| EP-2284210-A1 | CHARGE CONVERSIONAL TERNARY POLYPLEX | The University of Tokyo (JP) | 2011-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060123-A1 | CHARGE CONVERSIONAL TERNARY POLYPLEX | PARN, PARG, NCAPD2 | TSHR 4445/4885KDM4E 3902/4885CPB1 738/4885 |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | CD274, PDCD1LG2, PDCD1 | TSHR 1768/4885KDM4E 1009/4885CPB1 3570/4885 |
| US-20220031859-A1 | HERBOXIDIENE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | CD74, HPGD, HLA-DRB1 | TSHR 2959/4885KDM4E 1529/4885CPB1 3612/4885 |
| US-20260144888-A1 | USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE | IGF1R, CD44, MUC1 | TSHR 60/4885KDM4E 4172/4885CPB1 3689/4885 |
| US-11248054-B2 | Anti-IL1RAP antibodies and antibody drug conjugates | IL1RN, IL1R1, IL1A | TSHR 922/4885KDM4E 4317/4885CPB1 2772/4885 |
| US-11230610-B2 | Bivalent antibodies masked by coiled coils | COIL, CRYAB, UACA | TSHR 1813/4885KDM4E 2917/4885CPB1 73/4885 |
| US-20260139073-A1 | Antigen Binding Proteins | TNFSF11, TNFSF10, CD40 | TSHR 870/4885KDM4E 79/4885CPB1 1201/4885 |
| US-12624104-B2 | Compositions and methods for treating cancer with anti-CD19 immunotherapy | CD2, CD22, CD4 | TSHR 699/4885KDM4E 1536/4885CPB1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.